Esther I. van Vliet - Concepedia

Author

Esther I. van Vliet

Also Known As

E I van Vliet, E. I. van Vliet, Esther I. van Vliet

Publications

668

Citations

H-Index

Concepts

All Affiliations

Esther I. van Vliet is an author at Erasmus MC specializing in medicine, cell signaling, and radiation oncology.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	75
2	Pharmacology	1	1	75
3	Cell Signaling	1	1	75
4	Signal Transduction	1	1	75
5	Radiation Oncology	1	1	75

Esther I. van Vliet

Publications

358

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate Esther I. van Vliet, Casper H.J. van Eijck, Ronald R. de Krijger, Journal of Nuclear Medicine	2015	120
Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy E. van Schaik, Esther I. van Vliet, Richard A. Feelders, The Journal of Clinical Endocrinology & Metabolism	2011	98
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen, Best Practice & Research Clinical Gastroenterology Signal TransductionMedicineNeuropeptide ReceptorPeptide TherapeuticNon-peptide Ligand	2012	75
Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate Esther I. van Vliet, Eric P. Krenning, Jaap J.M. Teunissen, Journal of Nuclear Medicine	2013	45
Tumor Response Assessment to Treatment with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions Esther I. van Vliet, John J. Hermans, Maria A. de Ridder, Journal of Nuclear Medicine	2012	20

Page 1